BamSEC and AlphaSense Join Forces
Learn More

Voyager Therapeutics Inc.

NASDAQ: VYGR    
Share price (12/20/24): $5.75    
Market cap (12/20/24): $314 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. ​ First Amendment to Option and License Agreement ​
12/34/56
EX-10.1
from 10-Q 6 pages ​ Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. ​
12/34/56
EX-10.1
from 10-Q 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. First Amendment to Collaboration and License Agreement
12/34/56
EX-10.1
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.4
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 5 pages ​ Amendment No. 4 to Consulting Agreement ​
12/34/56
EX-10.1
from 8-K 11 pages Transition, Separation and Release of Claims Agreement
12/34/56
EX-10.1
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.47
from 10-K 5 pages Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.46
from 10-K 2 pages ​ Amendment No. 2 ​ Consulting Agreement ​
12/34/56
EX-10.45
from 10-K 16 pages Investor Agreement
12/34/56
EX-10.44
from 10-K 36 pages Stock Purchase Agreement by and Between Novartis Pharma AG and Voyager Therapeutics, Inc. Dated as of December 28, 2023 ​ ​ ​ ​ ​ ​
12/34/56
EX-10.43
from 10-K 75 pages License and Collaboration Agreement
12/34/56
EX-10.1
from 8-K 10 pages 75 Hayden Avenue Lexington, Massachusetts 02421 (The “Building”) First Amendment
12/34/56
EX-10.1
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.5
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.46
from 10-K 21 pages Investor Agreement
12/34/56
EX-10.45
from 10-K 94 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. ​ Collaboration and License Agreement ​ by and Between Voyager Therapeutics, Inc. ​ and Neurocrine Biosciences, Inc. ​
12/34/56
EX-10.44
from 10-K 34 pages Stock Purchase Agreement by and Between Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc. Dated as of January 8, 2023 ​
12/34/56
EX-10.43
from 10-K 27 pages ​ Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. ​ Dated 3november 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patent and Know-How Licence ​ ​ ​ ​ ​ ​ ​ ​ ​ Between ​ Touchlight Ip Limited ​ and ​ Voyager Therapeutics, Inc. ​
12/34/56